Tags |
|
|
Links |
|
|
Top Articles - Annuities - Don't Put Your IRA In A Variable Annuity - Part 2
Last week I shared with you the real reason advisors push IRA accounts into variable annuities: the commission. If you’re getting ready to retire with a large IRA rollover, or your current IRA accou
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
nt is nearing the end of any surrender penalties, chances are you’ll be pitched this product. So this week I’m going to reveal more secrets about the truth behind the variable annuity sales pitch.
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
One of the biggest draws advisors use to get you to take the plunge is the promise of the big bonus. They’ll pay you 6%, 8% or even 10% extra, right up front, just for putting your money into their
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
variable annuity. Sounds great, doesn’t it? Who wouldn’t want such a big boost to their nest egg, especially with the stock market returns of late? But remember, there’s no such thing as a free lunc
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
h.
In return for this lovely bonus, you end up paying higher recurring annual fees, usually .15% higher (or more) than regular variable annuities. These fees are charged on all of the money in the
In return for this lovely bonus, you end up paying higher recurring annual fees, usually .15% higher (or more) than regular variable annuities. These fees are charged on all of the money in the
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
annuity and are a continued drag on performance. Surrender penalties are higher and longer, too. The truth is that when you take into account the increased fees and the extra years you have to stay
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
in the annuity, you really aren’t getting a ‘bonus’ at all!
These bonuses aren’t just used to entice you to invest your original IRA rollover when you retire. They’re also used to encourage you to
These bonuses aren’t just used to entice you to invest your original IRA rollover when you retire. They’re also used to encourage you to
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ransfer out of an annuity you already own that’s still in the penalty period. Advisors will tell you that the bonus on this ‘new-and-improved’ annuity will ‘pay you back’ for the penalty you’ll pay
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
to get out of your old commission-based investment. The truth is, by getting you to switch to the ‘bonus’ annuity, they earn a fat fee up-front. You end up with pretty much the same thing you had bu
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
t now are locked into it for much longer. What kind of a ‘deal’ is that?
The promise of multiple investment choices is another feature of the variable annuity sales pitch that doesn’t live up to i
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ts claim. It’s true that many variable annuities offer a multitude of mutual fund choices in various sub-accounts, including funds investing in bonds, small companies, large companies, international
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
stocks and more. Surely out of all of these choices, anyone could create a balanced well-performing portfolio, right?
Not necessarily. It’s sort of like fishing. Who wants to fish in a pond full o
Not necessarily. It’s sort of like fishing. Who wants to fish in a pond full o
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
f minnows? Wouldn’t you rather drop your line where you have a greater chance of catching the big one? The mutual fund universe is full of thousands of choices. But only a small group of them are co
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
nsistent top performers. Unfortunately, few variable annuities offer these big fish.
Some variable annuities feature a well-known fund already offered to the general public. But beware. This same f
Some variable annuities feature a well-known fund already offered to the general public. But beware. This same f
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
nd will have much higher management fees within the annuity than it does outside of it, hampering its performance. I believe insurance companies make special deals with mutual fund companies to gain
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
access to their management and then charge higher fees.
When you invest your money into a variable annuity, you’ll no longer have control over the choices at your disposal. The insurance company c
When you invest your money into a variable annuity, you’ll no longer have control over the choices at your disposal. The insurance company c
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
an change the investment choices whenever they want to and you have no recourse. Since your money is locked in for years, it will be very costly to change course a few years down the road should you
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
be dissatisfied. What kind of choice is that?
So here’s the bottom line: variable annuities make big promises but don’t really deliver. Every feature they offer -- be it a big bonus, a multitude o
So here’s the bottom line: variable annuities make big promises but don’t really deliver. Every feature they offer -- be it a big bonus, a multitude o
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
f investment choices, death benefit, or a guaranteed income stream -- comes at a very high price. High management fees and long, costly surrender penalties hinder your performance and rob you of you
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
r flexibility and control. The ones making the most money off of variable annuities are the advisors and the insurance companies. It turns out that variable annuities are a great investment—for them
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/102015/toparticles-Annuities--Dont-Put-Your-IRA-In-A-Variable-Annuity--Part-2.html">Annuities - Don't Put Your IRA In A Variable Annuity - Part 2</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/102015/toparticles-Annuities--Dont-Put-Your-IRA-In-A-Variable-Annuity--Part-2.html]Annuities - Don't Put Your IRA In A Variable Annuity - Part 2[/url]
Related Articles:
Finding Your Way: How to get Support When Creating a New Business
Get Your Business Noticed - The Right Way!
Payday Loans And Other Credit Possibilities - Commercial Loans
Bookmark it:
|